Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Novel targeted therapies for Parkinson's disease | Molecular Medicine | Full Text
Frontiers | Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
Sanofi halts venglustat clinical programme in kidney disease
venglustat - Drug Hunter
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers - Peterschmitt - 2021 - Clinical Pharmacology in Drug Development - Wiley Online Library
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Biomolecules | Free Full-Text | The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
Venglustat (GZ402671) for Fabry Disease Clinical Trial 2023 | Power
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
Venglustat Lowers Gb3 With No Signs of Disease Progression in Trial | Venglustat Led to Long-term Benefits in 5 of 6 Men in Phase 2 Trial | Fabry Disease News
Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
PERIDOT – Patient ExpeRIence in fabry Disease On venglustaT | M.A.G.I.C Clinic
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
IJMS | Free Full-Text | Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders
Sanofi's venglustat fails another trial, ending pursuit of kidney disease | Fierce Biotech
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC